drugset / Trial / NCT04241393

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393

Phase 1 Completed 12 enrolled Cerevel Therapeutics, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of \[14C\] tavapadon.

Timeline

Start
2020-02-04
Primary completion
2020-11-08
Completion
2020-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavapadon Small molecule 2.5 mg Oral

Indications

No indication recorded.